MedPath

U3-1402 in Metastatic or Unresectable Non-Small Cell Lung Cancer

Phase 1
Recruiting
Conditions
Non-Small Cell Lung Cancer (NSCLC)
Interventions
Drug: HER3-DXd (FL-DP)
Drug: HER3-DXd (CTM-1 Lyo-DP)
Drug: HER3-DXd (CTM-3 Lyo-DP)
Registration Number
NCT03260491
Lead Sponsor
Daiichi Sankyo
Brief Summary

This study was designed to evaluate safety and antitumor activity of HER3-DXd in two parts: Dose Escalation and Dose Expansion.

In Dose Escalation, HER3-DXd was evaluated in participants with metastatic or unresectable NSCLC with epidermal growth factor receptor (EGFR) activating mutation after disease progression during/after EGFR tyrosine kinase inhibitor (TKI) therapy.

In Dose Expansion, HER3-DXd will be evaluated in participants with metastatic or unresectable NSCLC with EGFR activating mutation or squamous or non-squamous NSCLC (ie, without EGFR-activating mutations) with disease progression during/after systemic treatment for locally advanced or metastatic disease.

In addition, HER3-DXd will be evaluated in participants with locally advanced or metastatic NSCLC whose tumors harbor a KRAS-G12C mutation after progression on the most recent line of therapy (Cohort 5).

Detailed Description

The primary objectives are:

* For Dose Escalation, to assess the safety and tolerability of HER3-DXd in the study population and to determine the recommended dose for expansion (RDE) of HER3-DXd in the study population

* For Dose Expansion, to investigate the antitumor activity of HER3-DXd

* For Cohort 5, investigate the antitumor activity of HER3-DXd in participants with locally advanced or metastatic NSCLC whose tumors harbor a KRAS-G12C mutation after the failure of targeted therapy

The number of treatment cycles is not fixed in this study. Participants will continue study treatment (for approximately 36 months) until they decide not to (withdraw consent), their disease gets worse \[progressive disease (PD)\], or side effects become unacceptable (unacceptable toxicity) or other stopping reasons have been met.

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
309
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
SEQUENTIAL
Arm && Interventions
GroupInterventionDescription
Dose Escalation: Cohort 1, 3.2 mg/kgHER3-DXd (FL-DP)Participants in the Dose Escalation Cohort 1 will receive HER3-DXd intravenously (IV) once every three weeks at 3.2 mg/kg.
Dose Escalation: Cohort 2, 4.8 mg/kgHER3-DXd (FL-DP)Participants in Dose Escalation Cohort 2 will receive HER3-DXd intravenously (IV) once every three weeks at 4.8 mg/kg.
Dose Escalation: Cohort 3, 5.6 mg/kgHER3-DXd (FL-DP)Participants in Dose Escalation Cohort 3 will receive HER3-DXd intravenously (IV) once every three weeks at 5.6 mg/kg.
Dose Escalation: Cohort 4, 6.4 mg/kgHER3-DXd (FL-DP)Participants in Dose Escalation Cohort 3 will receive HER3-DXd intravenously (IV) once every three weeks at 6.4 mg/kg.
Dose Expansion: Cohort 1, EGFR mutantHER3-DXd (CTM-1 Lyo-DP)Participants with adenocarcinoma NSCLC with EGFR mutations in the Dose Expansion Cohort 1 will receive HER3-DXd IV once every three weeks at the established recommended dose for expansion (RDE).
Dose Expansion: Cohort 2, EGFR wild-typeHER3-DXd (CTM-1 Lyo-DP)Participants with squamous or non-squamous NSCLC without EGFR-activating mutations in the Dose Expansion Cohort 2 will receive HER3-DXd IV once every three weeks at the established recommended dose for expansion (RDE).
Dose Expansion: Cohort 3a, EGFR mutantHER3-DXd (CTM-1 Lyo-DP)Randomized participants with NSCLC and EGFR mutations in the Dose Expansion Cohort 3a will receive HER3-DXd IV once every three weeks at the established recommended dose for expansion (RDE) or, if applicable, adjusted RDE (aRDE).
Dose Expansion: Cohort 3b, EGFR mutantHER3-DXd (CTM-1 Lyo-DP)Randomized participants with NSCLC and EGFR mutations in the Dose Expansion Cohort 3b will receive HER3-DXd IV once every three weeks following an up-titration regimen (Cycle 1, Day 1: 57% of RDE or aRDE; Cycle 2, Day 1: 86% of RDE or, if applicable aRDE; Cycle 3 and subsequent cycles, Day 1: 114% of RDE or aRDE).
Dose Expansion: Cohort 4, EGFR mutantHER3-DXd (CTM-3 Lyo-DP)Participants with NSCLC (including any histology other than small-cell or combined small-cell and non-small cell) with an EGFR-activating mutation will receive HER3-DXd IV at 5.6 mg/kg every 3 weeks.
Dose Expansion: Cohort 5, KRAS-G12C mutant NSCLCHER3-DXd (CTM-3 Lyo-DP)Participants with locally advanced or metastatic NSCLC whose tumors harbor a KRAS-G12C mutation and that have progressed on the most recent line of therapy will receive HER3-DXd IV at 5.6 mg/kg every 3 weeks.
Primary Outcome Measures
NameTimeMethod
Dose-limiting toxicities (DLTs) during dose escalation21 days of Cycle 1
Summary of adverse events during dose escalationBy the global end of trial date, approximately within 36 months
Overall response rate (ORR) assessed by Blinded Independent Central Review (BICR) Committee during dose expansion (Dose Expansion Cohorts 1, 2, 3a, 3b, and Cohort 5)Approximately within 36 months

ORR will be evaluated using RECIST v1.1.

Maximum serum concentration (Cmax) of HER3-DXd, total anti-HER3 antibody, and MAAA-1181a during dose expansion (Cohort 4)During the first 5 cycles (each cycle is 21 days), including an intensive sampling schedule: pre-dose, end of infusion (EOI), 2 hour (hr), 4 hr, 8 hr post infusion, Day 8, and Day 15.
Area under the serum concentration-time curve from time 0 extrapolated to infinity (AUCinf) and up to last quantifiable time (AUC[last]) of HER3-DXd, total anti-HER3 antibody, and MAAA-1181a during dose expansion (Cohort 4)During the first 5 cycles (each cycle is 21 days), including an intensive sampling schedule: pre-dose, end of infusion (EOI), 2 hour (hr), 4 hr, 8 hr post infusion, Day 8, and Day 15.
Secondary Outcome Measures
NameTimeMethod
Maximum serum concentration (Cmax) of HER3-DXd, total anti-HER3 antibody, and MAAA-1181a during dose escalationDuring the first 5 cycles (each cycle is 21 days), including an intensive sampling schedule: pre-dose, end of infusion (EOI), 2 hour (hr), 4 hr, 8 hr post infusion, Day 8, and Day 15.
Time of maximum concentration (Tmax) of HER3-DXd, total anti-HER3 antibody, and MAAA-1181a during dose escalationDuring the first 5 cycles (each cycle is 21 days), including an intensive sampling schedule: pre-dose, end of infusion (EOI), 2 hour (hr), 4 hr, 8 hr post infusion, Day 8, and Day 15.
Area under the serum concentration-time curve from time 0 to 21 days (AUC[0-21]) and up to last quantifiable time (AUC[last]) of HER3-DXd, total anti-HER3 antibody, and MAAA-1181a during dose escalationDuring the first 5 cycles (each cycle is 21 days), including an intensive sampling schedule: pre-dose, end of infusion (EOI), 2 hour (hr), 4 hr, 8 hr post infusion, Day 8, and Day 15.
Overall response rate (ORR) during dose escalationApproximately within 36 months

Evaluated using RECIST 1.1

Disease control rate (DCR) during dose escalationApproximately within 36 months
Duration of response (DOR) during dose escalationApproximately within 36 months
Time to response (TTR) during dose escalationApproximately within 36 months
Progression free survival (PFS) during dose escalationApproximately within 36 months
Overall Survival (OS) during dose escalationApproximately within 36 months
Summary of adverse events during dose expansion (Dose Expansion Cohorts 1-4 and Cohort 5)By the global end of trial date, approximately within 60 months
Maximum serum concentration (Cmax) of HER3-DXd, total anti-HER3 antibody, and MAAA-1181a during dose expansion (Dose Expansion Cohorts 1-3 and Cohort 5)During the first 5 cycles (each cycle is 21 days), including an intensive sampling schedule: pre-dose, end of infusion (EOI), 2 hour (hr), 4 hr, 8 hr post infusion, Day 8, and Day 15.
Time of maximum concentration (Tmax) of HER3-DXd, total anti-HER3 antibody, and MAAA-1181a during dose expansion (Dose Expansion Cohorts 1-4 and Cohort 5)During the first 5 cycles (each cycle is 21 days), including an intensive sampling schedule: pre-dose, end of infusion (EOI), 2 hour (hr), 4 hr, 8 hr post infusion, Day 8, and Day 15.
Area under the serum concentration-time curve from time 0 to 21 days (AUC[0-21]) and up to last quantifiable time (AUC[last]) of HER3-DXd, total anti-HER3 antibody, and MAAA-1181a during dose expansion (Dose Expansion Cohorts 1-3 and Cohort 5)During the first 5 cycles (each cycle is 21 days), including an intensive sampling schedule: pre-dose, end of infusion (EOI), 2 hour (hr), 4 hr, 8 hr post infusion, Day 8, and Day 15.
Overall response rate (ORR) by Investigator during dose expansion (Dose Expansion Cohorts 1-4 and Cohort 5)Approximately within 60 months

Evaluated using RECIST 1.1

Disease control rate (DCR) during dose expansion (Dose Expansion Cohorts 1-4 and Cohort 5)Approximately within 60 months
Duration of response (DOR) during dose expansion (Dose Expansion Cohorts 1-4 and Cohort 5)Approximately within 60 months
Time to response (TTR) during dose expansion (Dose Expansion Cohorts 1-4 and Cohort 5)Approximately within 60 months
Progression free survival (PFS) during dose expansion (Dose Expansion Cohorts 1-4 and Cohort 5)Approximately within 60 months
Overall survival (OS) during dose expansion (Dose Expansion Cohorts 1-4 and Cohort 5)Approximately within 60 months
Percentage of participants who are anti-drug antibody (ADA)-positive (baseline and post-baseline) and Percentage of participants who have treatment-emergent ADA during dose expansion (Cohort 4)Approximately within 60 months
Mean Change from Baseline in the NSCLC-SAQ Total Score (Cohort 5)Approximately within 60 months

The NSCLC-SAQ will assess symptom severity over the previous 7 days. Participants will respond using a 5-point verbal rating scale ranging from 0 "No (symptom) at all" to 4 "Very severe (symptom)" or from 0 "Never" to 4 "Always". NSCLC-SAQ total score is the sum of 5 domains (cough, pain, dyspnea, fatigue, and poor appetite) and ranges between 0 and 20. Higher scores indicate more severe symptomatology. Mean change from baseline in NSCLC-SAQ total score will be reported.

Proportions of Deteriorated, Stable, or Improved Symptoms from NSCLC-SAQ (Cohort 5)Approximately within 60 months
Proportions of Deteriorated, Stable, or Improved Symptoms from PRO-CTCAE (Cohort 5)Approximately within 60 months

Trial Locations

Locations (36)

City of Hope

🇺🇸

Duarte, California, United States

University of California San Diego

🇺🇸

La Jolla, California, United States

Pacific Shores Medical Group

🇺🇸

Long Beach, California, United States

Winship Cancer Institute of Emory University

🇺🇸

Atlanta, Georgia, United States

Massachusetts General Hospital

🇺🇸

Boston, Massachusetts, United States

Dana-Farber Cancer Institute

🇺🇸

Boston, Massachusetts, United States

Karmanos Cancer Institute

🇺🇸

Detroit, Michigan, United States

Henry Ford Hospital

🇺🇸

Detroit, Michigan, United States

NYU Langone Health - NYU Medical Oncology Associates

🇺🇸

New York, New York, United States

Memorial Sloan-Kettering Cancer Center

🇺🇸

New York, New York, United States

Gabrail Cancer Center (GCC) - Canton Facility

🇺🇸

Canton, Ohio, United States

University of Pittsburgh Medical Center (UPMC) - Hillman Cancer Center (University of Pittsburgh Cancer Institute (UPCI)

🇺🇸

Pittsburgh, Pennsylvania, United States

Sarah Cannon Research Institute/Tennesse Oncology

🇺🇸

Nashville, Tennessee, United States

Fred Hutchinson Cancer Center

🇺🇸

Seattle, Washington, United States

Northwest Medical Specialties

🇺🇸

Tacoma, Washington, United States

National Cancer Center Hospital East (NCCHE) - Kashiwa Campus

🇯🇵

Kashiwa-Shi, Japan

Kurume University - Kurume University Hospital - Respiratory Diseases Center

🇯🇵

Kurume-Shi, Japan

Kindai University Hospital

🇯🇵

Osaka, Japan

Shizuoka Cancer Center

🇯🇵

Shizuoka, Japan

Seoul National University Hospital

🇰🇷

Seoul, Korea, Republic of

Hospital Universitario Vall d'Hebron

🇪🇸

Barcelona, Spain

The Cancer Institute Hospital of Japanese Foundation for Cancer Research (JFCR)

🇯🇵

Tokyo, Japan

Netherlands Cancer Institute

🇳🇱

Amsterdam, Netherlands

Clinica Universidad Navarra(Madrid)

🇪🇸

Madrid, Spain

Clínica Universidad de Navarra (Pamplona)

🇪🇸

Pamplona, Spain

Chung Shan Medical University Hospital

🇨🇳

Taichung, Taiwan

Asan Medical Center

🇰🇷

Seoul, Korea, Republic of

Samsung Medical Center

🇰🇷

Seoul, Korea, Republic of

NEXT Oncology - Hospital Quironsalud Barcelona

🇪🇸

Barcelona, Spain

Hospital General Universitario Gregorio Maranon (HGUGM)

🇪🇸

Madrid, Spain

Hospital Universitario 12 de Octubre

🇪🇸

Madrid, Spain

Hospital Ramón y Cajal

🇪🇸

Madrid, Spain

Hospital Universitario Madrid Sanchinarro - Centro Integral Oncologico Clara Campal (CIOCC)

🇪🇸

Madrid, Spain

Hospital Universitario Quirónsalud Madrid

🇪🇸

Madrid, Spain

National Cheng Kung University Hospital

🇨🇳

Tainan, Taiwan

National Taiwan University Hospital

🇨🇳

Taipei, Taiwan

© Copyright 2025. All Rights Reserved by MedPath